A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.

X Tonnar; Cornelius F Waller

doi:10.1159/000548479

December 1, 2025

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.

View at Publisher

Ask AI

Bookmark

Share

Key Points

Hemoglobin increased rapidly after pausing Alectinib, showing a positive outcome.
The patient maintained stable disease during the switch to Lorlatinib, highlighting treatment efficacy.
This case illustrates the potential benefits of switching therapies in managing hemolytic anemia.
Future assessments may further clarify management strategies for lung cancer with hemolytic anemia.

Implication

Case report highlights hemoglobin increase after Alectinib pause in lung cancer, indicating Lorlatinib's efficacy with no relapse.

Abstract

This is the first report describing a rapid increase in hemoglobin after pausing alectinib and no relapse of hemolysis after switching to lorlatinib, while the lung cancer remained stable (stable disease).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tonnar et al. (2025) studied this question.

synapsesocial.com/papers/6930e8cdea1aef094cca380a https://doi.org/10.1159/000548479

View at Publisher

Ask AI

Bookmark

Share

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.

Key Points

Implication

Abstract

Discussion

Cite This Study

A Rare Case of Hemolytic Anemia after Alectinib That Did Not Recur after Switching to Lorlatinib.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading